Novonesis (NSIS) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
1 May, 2026Market opportunity and growth drivers
Biosolutions market estimated at ~€60bn, with potential in the €1,000bn specialty chemicals & ingredients market.
Structural shifts such as regulatory changes, population growth, and demand for fossil-free solutions are accelerating adoption.
Key growth drivers include sustainable agriculture, clean label, reduced food waste, alternative proteins, and climate risk mitigation.
Products reach over half the world's population, addressing needs in food, health, agriculture, textiles, and more.
Strategic pillars and financial targets
Three pillars: grow the core, accelerate biosolutions market, and enhance distinctive position.
Organic sales CAGR targeted at 6-9% through 2030.
Adjusted EBITDA margin goal of ~39% and adjusted ROIC (excluding goodwill) of ~16% by 2030.
Growth driven by innovation, market penetration, upselling, and new applications.
Innovation and technology platform
Strong focus on customer centricity, innovation leadership, and world-class scale.
Expanding technology platform with investments in bacteria, yeast, proteins, enzymes, and probiotics.
Mastery in engineering and scaling up biological strains for diverse biosolutions.
Over 200 late-stage innovation projects and 20% of revenue from products launched in the last 5 years.
Latest events from Novonesis
- Biosolutions in Household Care drive growth through innovation, sustainability, and market expansion.NSIS
Investor presentation - 7% organic sales growth and 37.8% EBITDA margin support a strong 2026 outlook.NSIS
Q1 2026 - 7% organic sales growth and 37.1% EBITDA margin in 2025; 2026 outlook remains strong.NSIS
Q4 2025 - Diversification and innovation drive growth in energy, with strong prospects in sustainable fuels.NSIS
Status Update - 9% organic sales growth YTD 2024; full-year outlook raised to upper end of 7-8%.NSIS
Q3 2024 - 7% organic sales growth, margin gains, and innovation led to a raised 2024 outlook.NSIS
Q2 2024 - 2024 outlook upgraded with higher growth and margins, driven by innovation and synergies.NSIS
CMD 2024 - Full control of animal biosolutions value chain drives growth, innovation, and margin gains.NSIS
M&A Announcement - 11% organic sales growth, margin expansion, and a major acquisition highlight Q1 2025.NSIS
Q1 2025